Home / Resource Library / Durable Responses Observed with JAK Inhibition in T-Cell LymphomasDurable Responses Observed with JAK Inhibition in T-Cell Lymphomas Preliminary results of a phase II trial of ruxolitinib for treatment of relapsed T-cell lymphomas